Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • SGLT2i for heart failure

HF prevalence in diabetes patients is underestimated in everyday clinical practice

    • Cardiology
    • Congress Reports
    • Endocrinology and Diabetology
    • General Internal Medicine
    • RX
  • 4 minute read

SGLT2 inhibitors can significantly reduce the risk of hospitalization for heart failure (HF) and death from cardiovascular causes in patients with diabetes and HF. However, the diagnosis of HF is difficult. Scientists from St. Gallen therefore wanted to determine the prevalence of heart failure in patients with diabetes with and without SGLT2i in order to establish whether treatment guidelines need to be tightened and regular screening for HF introduced.

The guidelines of the European Society of Cardiology (ESC) recommend treating patients with heart failure first line with an SGLT2 inhibitor, regardless of whether they have type 2 diabetes or not. This applies primarily to patients with a reduced left ventricular ejection fraction (HFrEF), but recent clinical studies have also shown similar benefits for patients with a slightly reduced (HFmrEF) or preserved (HFpEF) ejection fraction, explained Dr. Frida Renström from the Department of Endocrinology, Diabetology, Osteology and Metabolic Diseases at the Cantonal Hospital of St. Gallen [1].

“The clinical guidelines are designed to be quite simple, but translating them into clinical practice is complicated because the actual diagnosis of heart failure is challenging.” It is a condition without specific signs and symptoms that can often be attributed to other pre-existing complications in patients with type 2 diabetes. Heart failure therefore often remains unrecognized and the prevalence in this patient population is therefore not really clear, the expert explained.

The aim of her study was therefore to find out whether regular screening for heart failure in patients with diabetes is necessary in tertiary diabetes care and whether the treatment guidelines need to be supplemented accordingly.

SwissDiab participants were screened for HF

Their study was embedded in the Swiss Diabetes Registry (SwissDiab), a multicenter, longitudinal observational study of outpatients with diabetes treated in tertiary care centers. Over an 18-month period, all patients attending an annual SwissDiab visit were evaluated for heart failure based on the diagnostic algorithm recommended by the ESC. Accordingly, patients with at least one of the symptoms

  • arterial hypertension,
  • Orthopnea,
  • nocturnal dyspnea,
  • Treatment with diuretics,
  • Rattling noises,
  • bilateral ankle edema,
  • Heart murmur or
  • Jugular vein dilation

plus an NT-proBNP ≥125 ng/l were referred to the Department of Cardiology for echocardiography and clinical evaluation of HF, with further stratification according to HFpEF, HFmrEF and HFrEF. LDL cholesterol was estimated on the basis of the Friedewald equation.

Patients who had already been diagnosed with heart failure or who had coronary heart disease and who had undergone an echocardiogram within the last 2 years were not re-examined. In these cases, the data was looked up in the medical records. Heart failure was diagnosed on the basis of the left ventricular ejection fraction (LVEF):

  • HFrEF = LVEF ≤40%
  • HFmrEF = LVEF 41-49%
  • HFpEF = LVEF ≥50% + structural and/or functional cardiac abnormalities

During the 18-month period, 555 SwissDiab patients were referred. 21 patients had to be excluded due to missing data. The mean age was 61 years, 30% were female, the majority of 60% had type 2 diabetes, and the time since diagnosis was 14 years. The average BMI was 28.4 kg/m2, the HbA1c value was 7.1% and the LDL cholesterol was 2.1 mmol/l. 21.7% of the participants smoked.

“Of these patients, 11.2% (n=60) were diagnosed with heart failure, the majority – almost 57% (n=34) – had a preserved ejection fraction and 32% (n=19) had HFrEF,” explained Dr. Renström. The prevalence by diabetes type was 2.4% for type 1 diabetes (n=4), 16% for type 2 diabetes (n=51) and 10.6% (n=5) for other diabetes types. Of the HF cases identified, 60% (n=36) were newly diagnosed in this study, most of whom (83.3%) had type 2 diabetes. Looking at the prevalent cases, the majority had heart failure with reduced ejection fraction, while almost 78% of the newly diagnosed patients had heart failure with preserved ejection fraction (HFpEF: n=28; HFmrEF: n=4; HFrEF: n=4). Excluding patients with prevalent heart failure, this screening algorithm had a positive predictive value of almost 38%. Of the patients with prevalent heart failure, 50% were taking an SGLT2 inhibitor, two out of three patients had HFmrEF and 10 out of 15 had HFrEF. None of the group with a known diagnosis of HF had heart failure with preserved ejection fraction. All patients with HF who were treated with SGLT2i were type 2 diabetics.

One in six type 2 diabetics with HF

Approximately one in ten outpatients with diabetes in tertiary care who were included in SwissDiab had heart failure. In terms of type 2 diabetes only, it was one in six. Three out of five cases had not been previously diagnosed and had a preserved ejection fraction. Half of patients with previously diagnosed heart failure and two out of three patients with known HFrEF received an SGLT2 inhibitor, compared to less than one in three patients with HF overall.

Considering that the majority with HF were undiagnosed and half of patients with known HF were not receiving SGLT2i treatment, the results would indicate the need to raise awareness of HF and treatment in clinical practice.

Congress: EASD 2023

Source:

  1. Renström F: Short Oral Discussion “Prevalence of heart failure in patients with diabetes: a SwissDiab study”; EASD Congress 2023, Hamburg, 4.10.2023.

InFo DIABETOLOGY & ENDOCRINOLOGY 2024; 1(1): 30 (published on 13.2.24, ahead of print)

Autoren
  • Jens Dehn
Publikation
  • InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
  • cardiovascular risk
  • Diabetes
  • Heart failure
  • HF
  • SGLT2 inhibitors
  • SwissDiab
Previous Article
  • Cold plasma for chronic wounds

Impressive evidence base of effects that promote wound healing

  • Congress Reports
  • Dermatology and venereology
  • Endocrinology and Diabetology
  • Physical medicine and rehabilitation
  • RX
  • Studies
View Post
Next Article
  • Study report: Risk factors for hand eczema

Population-based data provides valuable new insights

  • Allergology and clinical immunology
  • Dermatology and venereology
  • Education
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
View Post
  • 3 min
  • Public Health

Outpatient care in Switzerland: situation report

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
View Post
  • 3 min
  • Bladder cancer

Tuberculosis vaccination reduces recurrences

    • Congress Reports
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
    • Urology
View Post
  • 4 min
  • Oral JAK-i in atopic dermatitis

Benefits and risks: What does the current data say?

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 17 min
  • Sleep-wake disorders in pneumology practice

Patience, knowledge and persistence in therapy

    • CME continuing education
    • General Internal Medicine
    • Neurology
    • Pneumology
    • RX
View Post
  • 9 min
  • Chronic lung diseases

Sarcopenia and malnutrition in the context of pneumological rehabilitation

    • CME continuing education
    • General Internal Medicine
    • Geriatrics
    • Nutrition
    • Pneumology
    • RX
    • Sports Medicine
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.